Literature DB >> 36058999

Fyn and Lyn gene polymorphisms impact the risk of thyroid cancer.

Asif Nisar1, Mahmood Akhtar Kayani1, Wajiha Nasir2, Azhar Mehmood1, Malik Waqar Ahmed1,3, Aamir Parvez1, Ishrat Mahjabeen4.   

Abstract

Thyroid cancer is the most common malignancy of the endocrine glands, and during last couple of decades, its incidence has risen alarmingly, across the globe. Etiology of thyroid cancer is still debatable. There are a few worth mentioning risk factors which contribute to initiation of abnormalities in thyroid gland leading to cancer. Genetic instability is major risk factors in thyroid carcinogenesis. Among the genetic factors, the Src family of genes (Src, Yes1, Fyn and Lyn) have been implicated in many cancers but there is little data regarding the association of these (Src, Yes1, Fyn and Lyn) genes with thyroid carcinogenesis. Fyn and Lyn genes of Src family found engaged in proliferation, migration, invasion, angiogenesis, and metastasis in different cancers. This study was planned to examine the effect of Fyn and Lyn SNPs on thyroid cancer risk in Pakistani population in 500 patients and 500 controls. Three polymorphisms of Fyn gene (rs6916861, rs2182644 and rs12910) and three polymorphisms of Lyn gene (rs2668011, rs45587541 and rs45489500) were analyzed using Tetra-primer ARMS-PCR followed by DNA sequencing. SNP rs6916861 of Fyn gene mutant genotype (CC) showed statistically significant threefold increased risk of thyroid cancer (P < 0.0001). In case of rs2182644 of Fyn gene, mutant genotype (AA) indicated statistically significant 17-fold increased risk of thyroid cancer (P < 0.0001). Statistically significant threefold increased risk of thyroid cancer was observed in genotype AC (P < 0.0001) of Fyn gene polymorphism rs12910. In SNP rs2668011 of Lyn gene, TT genotype showed statistically significant threefold increased risk of thyroid cancer (P < 0.0001). In case of rs45587541 of Lyn gene, GA genotypes showed statistically significant 11-fold increased risk in thyroid cancer (P < 0.0001). Haplotype analysis revealed that AAATAG*, AGACAG*, AGCCAA*, AGCCAG*, CAATAG*, CGCCAG* and CGCCGA* haplotypes of Fyn and Lyn polymorphisms are associated with increased thyroid cancer risk. These results showed that genotypes and allele distribution of Fyn and Lyn are significantly linked with increased thyroid cancer risk and could be genetic adjuster for said disease.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Fyn gene; Haplotype analysis; Linkage disequilibrium; Lyn gene; Thyroid cancer

Year:  2022        PMID: 36058999     DOI: 10.1007/s00438-022-01946-7

Source DB:  PubMed          Journal:  Mol Genet Genomics        ISSN: 1617-4623            Impact factor:   2.980


  45 in total

1.  Origin, functional role, and clinical impact of Fanconi anemia FANCA mutations.

Authors:  Maria Castella; Roser Pujol; Elsa Callén; Juan P Trujillo; José A Casado; Hans Gille; Francis P Lach; Arleen D Auerbach; Detlev Schindler; Javier Benítez; Beatriz Porto; Teresa Ferro; Arturo Muñoz; Julián Sevilla; Luis Madero; Elena Cela; Cristina Beléndez; Cristina Díaz de Heredia; Teresa Olivé; José Sánchez de Toledo; Isabel Badell; Montserrat Torrent; Jesús Estella; Angeles Dasí; Antonia Rodríguez-Villa; Pedro Gómez; José Barbot; María Tapia; Antonio Molinés; Angela Figuera; Juan A Bueren; Jordi Surrallés
Journal:  Blood       Date:  2011-01-27       Impact factor: 22.113

2.  TGFβ induces epithelial-mesenchymal transition of thyroid cancer cells by both the BRAF/MEK/ERK and Src/FAK pathways.

Authors:  Pablo Baquero; Eva Jiménez-Mora; Adrián Santos; Marina Lasa; Antonio Chiloeches
Journal:  Mol Carcinog       Date:  2015-09-21       Impact factor: 4.784

3.  Cancers of the Thyroid: Overview and Statistics in the United States and Oklahoma.

Authors:  Munim H Deen; Kaitlin M Burke; Amanda Janitz; Janis Campbell
Journal:  J Okla State Med Assoc       Date:  2016 Jul-Aug

Review 4.  AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY DISEASE STATE CLINICAL REVIEW: THE INCREASING INCIDENCE OF THYROID CANCER.

Authors:  Louise Davies; Luc G T Morris; Megan Haymart; Amy Y Chen; David Goldenberg; John Morris; Jennifer B Ogilvie; David J Terris; James Netterville; Richard J Wong; Gregory Randolph
Journal:  Endocr Pract       Date:  2015-06       Impact factor: 3.443

5.  Haplotype analysis of XRCC1 gene polymorphisms and the risk of thyroid carcinoma.

Authors:  Kashif Bashir; Romana Sarwar; Shazia Fatima; Soma Saeed; Ishrat Mahjabeen; Mahmood Akhtar Kayani
Journal:  J BUON       Date:  2018 Jan-Feb       Impact factor: 2.533

6.  A novel signaling pathway associated with Lyn, PI 3-kinase and Akt supports the proliferation of myeloma cells.

Authors:  Mohd S Iqbal; Naohiro Tsuyama; Masanori Obata; Hideaki Ishikawa
Journal:  Biochem Biophys Res Commun       Date:  2010-01-15       Impact factor: 3.575

Review 7.  Fyn is an important molecule in cancer pathogenesis and drug resistance.

Authors:  Daniel Elias; Henrik J Ditzel
Journal:  Pharmacol Res       Date:  2015-08-21       Impact factor: 7.658

8.  Cis-acting polymorphisms affect complex traits through modifications of microRNA regulation pathways.

Authors:  Matthias Arnold; Daniel C Ellwanger; Mara L Hartsperger; Arne Pfeufer; Volker Stümpflen
Journal:  PLoS One       Date:  2012-05-11       Impact factor: 3.240

9.  Association of Obesity and Thyroid Cancer at a Tertiary Care Hospital in Pakistan.

Authors:  Adnan Ali; Yumna Mirza; Urooj Faizan; Nida Zahid; Muhammad S Awan
Journal:  Cureus       Date:  2018-03-26

Review 10.  The dark matter of the cancer genome: aberrations in regulatory elements, untranslated regions, splice sites, non-coding RNA and synonymous mutations.

Authors:  Sven Diederichs; Lorenz Bartsch; Julia C Berkmann; Karin Fröse; Jana Heitmann; Caroline Hoppe; Deetje Iggena; Danny Jazmati; Philipp Karschnia; Miriam Linsenmeier; Thomas Maulhardt; Lino Möhrmann; Johannes Morstein; Stella V Paffenholz; Paula Röpenack; Timo Rückert; Ludger Sandig; Maximilian Schell; Anna Steinmann; Gjendine Voss; Jacqueline Wasmuth; Maria E Weinberger; Ramona Wullenkord
Journal:  EMBO Mol Med       Date:  2016-05-02       Impact factor: 12.137

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.